Journal article
TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II
S Siva, B Chesson, M Bressel, D Pryor, B Higgs, HM Reynolds, N Hardcastle, R Montgomery, B Vanneste, V Khoo, J Ruben, E Lau, MS Hofman, R De Abreu Lourenco, S Sridharan, NR Brook, J Martin, N Lawrentschuk, T Kron, F Foroudi
BMC Cancer | BMC | Published : 2018
Abstract
Background: Stereotactic ablative body radiotherapy (SABR) is a non-invasive alternative to surgery to control primary renal cell cancer (RCC) in patients that are medically inoperable or at high-risk of post-surgical dialysis. The objective of the FASTRACK II clinical trial is to investigate the efficacy of SABR for primary RCC. Methods: FASTRACK II is a single arm, multi-institutional phase II study. Seventy patients will be recruited over 3 years and followed for a total of 5 years. Eligible patients must have a biopsy confirmed diagnosis of primary RCC with a single lesion within a kidney, have ECOG performance ≤2 and be medically inoperable, high risk or decline surgery. Radiotherapy tr..
View full abstractRelated Projects (1)
Grants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This study underwent competitive peer review by the National Health and Medical Research Council (NHMRC) and was awarded governmental Cancer Australia funding (APP1139464). Additional seed funding and support for imaging substudies was provided by Varian (R) Industries.